$BCTX update: Bria-PROS+ (prostate cancer) moves closer to clinic after completion of manufacturing for trial supply.
➡️ Phase 1/2a study expected soon
➡️ Built on Bria-OTS+ platform
➡️ Preclinical data: activation of adaptive + innate immunity
➡️ Supported by $2M NCI grant
Another step expanding BriaCell’s immunotherapy pipeline.
NEWS: https://bit.ly/4wu2Z7k